Continuing Education Activity

Cancer is one of the three major causes of death after an organ transplant. Cardiovascular disease and infection are the other two reasons for death after an organ transplant, but they both are decreasing in frequency because of effective screening, prophylaxis, and interventional therapies. Knowledge of post-transplant malignancy is inadequate regarding early detection and lack of established guidelines. In this activity, we focus on the epidemiology, pathophysiology, presentation, diagnosis, screening and highlight the role of the interprofessional team in its treatment strategy.

Objectives:

• Identify the etiology of post-transplant cancer.
• Review the pathophysiology of post-transplant cancer.
• Outline the treatment and management options available for post-transplant cancer.
• Discuss interprofessional team strategies for improving care coordination and communication to advance the treatment of post-transplant cancer and improve outcomes.

Introduction

Organ transplant is the only way to extend the lives of many patients with end-stage organ failure. This procedure is not without the associated risks involved since the time of its inception. Cancer is one of the three major causes of death after an organ transplant.[1] Cardiovascular disease and infection are the other two reasons for death after an organ transplant, but they both are decreasing in frequency because of effective screening, prophylaxis, and interventional therapies. Understanding of post-transplant malignancy is inadequate regarding early detection and lack of established guidelines. The risk factor is most elusive because of altered dynamics of immunity, host response, and different clinical presentation.  Studies have shown an overall two to four-fold elevated risk of cancer after the organ transplant.[2] The mechanisms involved in the oncogenesis are long-term immunosuppression leading to reduced immune surveillance of neoplastic cells, and the opportunistic post-transplant infections especially viral infections because of Epstein-Barr virus (EBV), Varicella, Cytomegalovirus (CMV), and Human herpesvirus (HHV)-8, etc.[3] Physicians and patients face a challenging problem that cancer after an organ transplant is more biologically aggressive and patients may receive less aggressive cancer treatment because of comorbidities and the fear of transplant rejection. In this article, we will discuss the epidemiology, pathophysiology, presentation, diagnosis, screening and treatment strategy for cancer after organ transplantation.

Etiology

The risk factors for post-transplant malignancy are the patient, transplant, and medication-related.

Patient-related Risk Factors

The advanced age of the patient is a well-described risk factor, and it is an established risk factor for the development of skin cancer. Sun exposure, prior history of cancer in a transplant recipient are also strong risk factors. Acuna et al. in their meta-analysis showed that pre-transplant malignancy correlates with an increased risk of cancer-specific mortality and of developing de novo malignancies after transplantation, compared with solid organ transplant recipients without a pretransplant malignancy.[4]  Smoking and alcohol consumption are risk factors for carcinogenesis and carry a high risk of mortality.[5] Viruses implicated in carcinogenesis include Epstein-Barr virus (EBV), human herpesvirus 8 (HHV-8), human papillomavirus (HPV), the Merkel cell polyomavirus, hepatitis B, and hepatitis C. EBV is implicated in the development of Hodgkin disease, Non-Hodgkin lymphoma, and other manifestations of PTLD, nasopharyngeal cancers and leiomyosarcomas.[6]

Transplant-related Risk Factors

Differences in the type of transplant (living versus deceased) correlate with cancer risk. Patients who receive kidneys from a living donor have a lower risk for genitourinary cancer and PTLD.[7] Donor transmission as a cause of post-transplant malignancy is a rare but is a documented way of carcinogenesis; melanoma, cancer of lung, breast, colon, rectum, kidney, Kaposi sarcoma, and glioblastoma multiforme all have been reported to be transmittable from donors.[8] 

Medication-related Risk Factors

The immunosuppressive drugs impair immunosurveillance of neoplastic cells and increase the incidence of virally induced malignancies. The type, intensity, and duration of immunosuppressive therapy all influence the rate of carcinogenesis. These immunosuppressive drugs, for example, biologic agents (anti-thymocyte globulin, basiliximab), corticosteroids, antimetabolites (azathioprine, mycophenolate mofetil), calcineurin inhibitors (cyclosporine, tacrolimus), and mTOR inhibitors (rapamycin [sirolimus], everolimus) all have been implicated.[9]

Epidemiology

The Israel Penn International Transplant Tumor Registry (IPITTR),[10] the largest and most comprehensive registry in the world records non-melanoma skin cancers (NMSCs) as the most prevalent cancer in post organ transplant state. Following is the list of various cancers associated with the organ transplant:

• Kaposi sarcoma
• Skin (nonmelanoma, nonepithelial)
• Non-Hodgkin lymphoma 
• Liver 
• Anus 
• Vulva 
• Lip 

Other common malignancies with a statistically significant (p<0.001) increase included 

• Lung 
• Kidney 
• Colon and rectum 
• Pancreas 
• Hodgkin's lymphoma 
• Melanoma 

Pathophysiology

Transplant-related malignancies arise from an interplay of immunologic and nonimmunologic risk factors. The following is a brief description of the various pathways for the oncogenesis:

1. Immunosuppressive agents and oncogenesis: calcineurin inhibitors stimulate carcinogenesis by inhibiting DNA repair mechanisms, apoptosis, and enhancing the production of interleukin 2 (IL-2), transforming growth factor (TGF), and vascular endothelial growth factor (VEGF). Transforming growth factor promotes tumor growth by regulating tumor cell invasion, metastatic potential, and VEGF stimulates neo-angiogenesis. Azathioprine increases cancer risk by causing post-replicative DNA mismatch repair. Sirolimus, everolimus and mycophenolate mofetil are not associated with an increased risk of cancer; they actually have antiproliferative properties.
2. Viral Infection and oncogenesis: Transplant patients are vulnerable to viral infection or reactivation of latent infection. EBV promotes the oncogenesis by reduced lymphocyte regulation, a lack of control of the oncogenic virus by EBV-specific CD81 cytotoxic T-cells, and proliferation of EBV-infected B cells. The mechanism by which HHV-8 induces oncogenesis has not been completely elucidated. HHV-8’s proinflammatory proteins might directly inhibit apoptosis and promote cell transformation.[11]

History and Physical

Although early cancer diagnosis may show improvement of cancer outcomes in the cancer population, the reduced life expectancy and multiple comorbidities that exist in organ transplant recipients regular physical examination and history are of paramount importance. On average, the age at diagnosis of post-transplant cancer is 40 years and the time from transplantation is the 3 to 5 years.[12] However, these numbers vary according to the cancer subtype, with lymphoma and Kaposi sarcoma occurring early after transplantation and epithelial cancers later on. The specific questions on history taking that are of paramount importance are the amount of high sun exposure, any skin health concerns, and the onset of irregular skin lesions, as they all point towards the onset of skin malignancy. Studies have shown that continued consumption of alcohol and smoking lead to early and aggressive squamous cell malignancy and urinary bladder cancer. If there is a concern for fever, weight loss or any neurological disturbance, then radiological investigations should be performed to rule out PTLD. If the patient endorses lower GI bleed, then threshold to examine colon to rule out malignancy should be low. The history taking in patients with solid organ transplant is more vigorous and frequent than the general population. Physical examination should be carried out keeping in mind all the secondary cancers that may arise. Regular skin and breast examination should be performed in the office, a digital rectal exam to detect early prostate cancer, and neurological examination to clinically rule out CNS lymphoma and PTLD.[13]

Treatment / Management

Screening and early detection of cancers is the best form of treatment. Below are the recommendations for the screening of the specific malignancy.[14]

1. Breast cancer: Women 50 to 69 years: annual screening mammography with or without clinical breast examination is the current recommendation. At age 40 to 49 years: the benefit of screening is less certain and the ultimate decision is up to the clinician and patient. In females above 70 years of age: annual screening is appropriate as long as estimated life expectancy is about 8 years.
2. Liver cancer: Patients with chronic hepatitis B or C and cirrhosis, serum AFP and liver ultrasound should be performed every 6 to 12 months.
3. PTLD: Complete history and physical examination should take place every three months, particularly in the first posttransplant year.
4. Anogenital: Early physical examination of the anogenital area, including a pelvic examination and cytologic studies for women. There is insufficient evidence to recommend either for or against screening anoscopy and biopsies of the anal epithelium.
5. Cervical: All women aged above 18 years and sexually active girls <18 years old should undergo an annual pelvic examination and Pap smear.
6. Skin cancers: Examination of skin, conjunctivae, and oropharyngeal mucosa annually; patients at higher risk (ethnicity, geographic area of residence or serologic positivity for HHV) may benefit from more frequent screening.

 Careful screening of the patient and donor before transplantation to help detect an underlying pre-existing malignancy is one of the effective ways to avoid dealing with this enigmatic problem later on. We have tried to summarize the broad topic of management and cancer in solid organ recipients into general recommendations;

Reduction of immunosuppression: Reduction or cessation of immunosuppressive therapy is useful primarily in patients who had a renal transplant since the loss of the graft to rejection is not a fatal event in these patients. Such measures may cause tumor regression sometimes such as  PTLD, some skin cancers, Kaposi sarcoma (KS).[15] The reduction in calcineurin inhibitor exposure may be important.

Anogenital cancers: In situ anogenital cancers can be treated with laser therapy, electrocautery, or topical fluorouracil. Invasive tumors require wide local excision (e.g., APR), with inguinal lymphadenectomy.

Visceral malignancy: Visceral malignancies are to receive treatment by standard surgical, radiotherapeutic, or chemotherapeutic modalities. 

Post-transplant lymphoproliferative disorder (PTLD): Management of PTLD deserves special mention as the treatment has undergone major changes over time. The main options for initial treatment are the reduction of immunosuppression, immunotherapy with the CD20 monoclonal antibody (rituximab), chemotherapy, radiation therapy, or a combination of these. The PTLD classifies into four types and treatment varies according to the type.

• Early lesions:  Reduction of immunosuppression alone suffices.
• Polymorphic PTLD: They express CD20, so besides the reduction in immunosuppression rituximab is advised. Surgery is reserved for patients with minimal localized residual disease.
• Monomorphic PTLD: For CD20+ PTLD, reduction in immunosuppression with rituximab and combination of systemic chemotherapy such as CHOP (cyclophosphamide, vincristine, prednisone) is the therapeutic recommendation. If the tumor is CD20 negative, then systemic chemotherapy is administered along with the reduction in immunosuppression. Surgery is only for patients with complications such as perforation or obstruction of the hollow viscus such as the bowel. 
• Classic Hodgkin lymphoma-like PTLD–Classic Hodgkin lymphoma-like PTLD is the least common form. Data regarding its management is lacking. Treatment is according to the protocols used for classic Hodgkin lymphoma.[16][17]

Differential Diagnosis

Differential diagnosis:

• PTLD: Infectious complications streptococcal pharyngitis and Infectious mononucleosis in an immunosuppressed individual presenting with fever, pharyngitis, and cervical lymphadenopathy closely mimic PTLD. Solid-organ recipients with opportunistic pulmonary infections such as aspergillosis and acute graft-versus-host disease may develop multiple lung parenchymal nodules and alveolar opacities that mimic PTLD on imaging studies. 
• Melanoma: Mucosal fungal lesions closely mimic mucosal melanoma, so the progression of lesion and cytology may be necessary to treat.
• Skin cancers: keratoacanthoma and solar (actinic) keratosis closely mimic squamous cell carcinoma; an excisional biopsy can differentiate between the two. 
• CNS Lymphoma: CMV or Toxoplasma are common viral and parasitic infections in an immunosuppressed individual, they present as ring-enhancing lesions in the brain and may be mistaken for primary or secondary CNS lymphoma.
• Benign conditions of the transplanted kidney, liver, and lungs can manifest as space-occupying lesions and mimic posttransplant malignancies. Renal pathologic conditions such as transplant-related fibrosis, acute pyelonephritis, and subcapsular hematoma may mimic malignancies un ultrasound and CT.
• Ischemia and reperfusion injury to the liver transplant may cause biliary necrosis and hepatic infarcts or micro-abscesses that may mimic recurrent HCCs at imaging studies.[18]

Prognosis

Malignant neoplasms after transplantation have different clinical features that are responsible for higher mortality. The Israel Penn International Transplant Tumor Registry showed that the stage-specific survival for cancer of colon, lung, breast, prostate, and bladder, was lower in patients after solid organ transplant compared with those without it. The 1-year adjusted survival of recipients with colorectal, prostate and non-small-cell lung cancer were 10%, 40%, and 20%, respectively, compared with 40%, 80%, and 30% in the general population.[19] Farrugia et al. reported that the overall risk of cancer death after transplantation was tenfold as compared to age- and sex-matched population.[20]

Complications

Complications because of post-transplant cancer are decreased quality of life, death, and increased healthcare spending.

Deterrence and Patient Education

The solid organ recipients should be counseled and taught to remain vigilant of this potential problem. The National Kidney Foundation conducted a survey about whether transplant recipients remembered receiving information about the risk of cancer and other complications. The results were not promising as only one-third of these patients recalled receiving information from a health care professional about cancer risks before the procedure. One fourth (23%) of all the patients learned about the risk of post-transplant cancer only after their surgery. Filling this void a priority and detailed conversation before transplant and on follow-up visits need to take place. The patients should receive counseling regarding the risk factors that can be controlled or manipulated (e.g., immunosuppressive drugs, untreated viral infections), there is a window of opportunity to prevent post-transplant cancers. Thus, lies the importance of constant patient education.[21] Providing education and screening tools for all patients in the postoperative period ensures an extension of the provider's knowledge into the hands of the patients.

Enhancing Healthcare Team Outcomes

Successful organ transplantation and good quality of life for patients requires all members of the healthcare team to work together to provide bedside care, education, physical and psychosocial support, and continued follow-up examinations. Educating residents, organ transplant coordinators, specialty trained nurses, pharmacists, and mid-level practitioners on the latest research are vital in promoting the best perioperative and postoperative care.[22]

Cancer screening and surveillance should be standard practice for healthcare policies in clinics and hospitals. All members of the team should be made aware of dermatological inspections, sun protection programs, and self-screening tools for all patients as a protocol in the posttransplant period. All the protocols should be standardized.[23]

Transplant nurses arrange follow up for these patients, provide education to the patients and their families, monitor patient status, and provide feedback to the team. Pharmacists counsel patients about side effects, screen for drug-drug interactions, and assess compliance. These measures improve outcomes. [Level 5]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Pilmore H, Dent H, Chang S, McDonald SP, Chadban SJ. Reduction in cardiovascular death after kidney transplantation. Transplantation. 2010 Apr 15;89(7):851-7. [PubMed: 20048695]

2.

Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007 Jul 07;370(9581):59-67. [PubMed: 17617273]

3.

Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009 Oct 15;125(8):1747-54. [PubMed: 19444916]

4.

Acuna SA, Huang JW, Daly C, Shah PS, Kim SJ, Baxter NN. Outcomes of Solid Organ Transplant Recipients With Preexisting Malignancies in Remission: A Systematic Review and Meta-Analysis. Transplantation. 2017 Mar;101(3):471-481. [PubMed: 27101077]

5.

Faure S, Herrero A, Jung B, Duny Y, Daures JP, Mura T, Assenat E, Bismuth M, Bouyabrine H, Donnadieu-Rigole H, Navarro F, Jaber S, Larrey D, Pageaux GP. Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. J Hepatol. 2012 Aug;57(2):306-12. [PubMed: 22521352]

6.

Starr SP. Immunology Update: Long-Term Care of Solid Organ Transplant Recipients. FP Essent. 2016 Nov;450:22-27. [PubMed: 27869439]

7.

Sprangers B, Nair V, Launay-Vacher V, Riella LV, Jhaveri KD. Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clin Kidney J. 2018 Jun;11(3):315-329. [PMC free article: PMC6007332] [PubMed: 29942495]

8.

Penn I. Malignant melanoma in organ allograft recipients. Transplantation. 1996 Jan 27;61(2):274-8. [PubMed: 8600636]

9.

Stallone G, Infante B, Grandaliano G. Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J. 2015 Oct;8(5):637-44. [PMC free article: PMC4581374] [PubMed: 26413294]

10.

Witherow BA, Roth GS, Carrozza MA, Freyberg RW, Kopke JE, Alloway RR, Buell JF, First MR, Gross TG, Hanaway MJ, Trofe J, Woodle ES, Beebe TM. The Israel Penn International Transplant Tumor Registry. AMIA Annu Symp Proc. 2003;2003:1053. [PMC free article: PMC1480060] [PubMed: 14728556]

11.

Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant. 2008 Nov;8(11):2205-11. [PubMed: 18801025]

12.

Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med. 2013 Jul 01;3(7) [PMC free article: PMC3685882] [PubMed: 23818517]

13.

EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant. 2002;17 Suppl 4:32, 34-6. [PubMed: 12091641]

14.

Acuna SA, Huang JW, Scott AL, Micic S, Daly C, Brezden-Masley C, Kim SJ, Baxter NN. Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. Am J Transplant. 2017 Jan;17(1):103-114. [PubMed: 27575845]

15.

Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant. 1993 Nov-Dec;12(6 Pt 2):S328-36. [PubMed: 8312352]

16.

Zafar SY, Howell DN, Gockerman JP. Malignancy after solid organ transplantation: an overview. Oncologist. 2008 Jul;13(7):769-78. [PubMed: 18614590]

17.

Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013 Sep;8(3):173-83. [PMC free article: PMC4831913] [PubMed: 23737188]

18.

Katabathina VS, Menias CO, Tammisetti VS, Lubner MG, Kielar A, Shaaban A, Mansour J, Surabhi VR, Hara AK. Malignancy after Solid Organ Transplantation: Comprehensive Imaging Review. Radiographics. 2016 Sep-Oct;36(5):1390-407. [PubMed: 27618321]

19.

Wong G, Chapman JR, Craig JC. Death from cancer: a sobering truth for patients with kidney transplants. Kidney Int. 2014 Jun;85(6):1262-4. [PubMed: 24875547]

20.

Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, Sharif A. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2014 Jun;85(6):1395-403. [PubMed: 24257690]

21.

Kauffman HM, Cherikh WS, Cheng Y. Posttransplantation malignancies: a problem, a challenge, and an opportunity. Liver Transpl. 2002 May;8(5):488-90. [PubMed: 12004350]

22.

Rashti SL. Themes in Literature Related to Incidence, Risk, and Prevention of Cancer in Solid-Organ Transplantation Recipients on Immunosuppressive Therapy. Cancer Nurs. 2019 Jan/Feb;42(1):E28-E35. [PubMed: 29334522]

23.

Hall EC, Pfeiffer RM, Segev DL, Engels EA. Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013 Jun 15;119(12):2300-8. [PMC free article: PMC4241498] [PubMed: 23559438]

Disclosure: Shekhar Gogna declares no relevant financial relationships with ineligible companies.

Disclosure: Karan Ramakrishna declares no relevant financial relationships with ineligible companies.

Disclosure: Savio John declares no relevant financial relationships with ineligible companies.